April 2023

Results for ribociclib, ponatinib, brexucabtagene autoleucel, and allo-HCT.

In breast cancer, approval for elacestrant and a new indication for sacituzumab govitecan; approval for pirtobrutinib for mantle cell lymphoma.

CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”

The Community Oncology Alliance celebrated its 20th year at the Community Oncology Conference held March 23-24, 2023, in Kissimmee, Florida.

Coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit.

Coverage from the American College of Cardiology Scientific Session Together With World Congress of Cardiology, held March 4-6, 2023, in New Orleans, Louisiana.

Coverage from the session of the Institute for Value-Based Medicine®, held in New York, New York, on February 8, 2023. The American Journal of Managed Care® presented the event in partnership with New York Cancer and Blood Specialists.

Evidence-Based Oncology™ (EBO) spoke with TailorMed's Ian Manners about the financial assistance and consumer protection landscape, and what the cost of cancer care means to patient experience and outcomes.

Evidence-Based Oncology (EBO) spoke with Len Lichtenfeld, MD, the chief medical officer for Jasper Health and a board member with CancerCare.

The CEO of Carolina Blood and Cancer Care Associates discusses challenges with the proposed Enhancing Oncology Model.

Oncologists express concerns about the replacement for the Oncology Care Model; the EOM is set to start July 1, 2023.

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.

Recent papers highlight possible role of inflammation in connections between COVID-19, cancer markers.

A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).

The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.

Long-term results show sustained benefit from the immunotherapy-TKI combination for patients with metastatic renal cell carcinoma regardless of risk profile or PD-L1 status.

Compared with sorafenib, a combination of sintilimab and a bevacizumab biosimilar improved responses in patients with unresectable hepatocellular carcinoma (HCC).